The biotechnology company ABL Bio signed a mega-deal and secured 11 times its annual revenue through a single license agreement. Its upfront payment by itself ranks in the top 5 among the technology export deals made by pharmaceutical and biopharmaceutical companies in Korea. When excluding the ones that have returned the rights, ABL Bio’s deal is the third-largest in upfront payments.

According to the Financial Supervisory Service on the 12th, ABL Bio signed a license agreement with Genzyme for ABL301, a bispecific antibody candidate for the treatment of Parkinson's disease and other neurodegenerative diseases. Genzyme is a fully owned subsidiary of Sanofi. Under the agreement, after ABL Bio completes th